Northeast Pharmaceutical Group announced that the company has received the "Approval Notification for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, and the listing application for the Active Pharmaceutical Ingredient Ertugliflozin has been approved. Ertugliflozin is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. This drug has better glucose-lowering effects, more stable metabolic characteristics, and better combined synergistic effects. This approval is beneficial for enriching the company's product pipeline and enhancing market competitiveness.